Immunotherapy with chemoradiation for recurring nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer has been confirmed by biopsy as recurring nasopharyngeal cancer
- The cancer came back more than 12 months after your first course of radiation ended
- Your tumor must be visible and measurable on CT or MRI scans
- You need enough body function: bone marrow, liver, and kidneys must be within allowed limits
- You must be well enough overall, with a performance score of at least 70
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests whether adding toripalimab (an immune therapy) to surgery helps people with recurrent nasopharyngeal cancer live longer or control the cancer better than surgery alone. You may qualify if your recurrence can be fully removed by surgery and it came back after a certain amount of time.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial tests giving chemotherapy before and after surgery for people whose nasal cancer has come back. The goal is to see if this approach helps remove the cancer more effectively and prevents it from returning again.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.